Home > Healthcare & Medical Devices > Peptide Therapeutics Market
Peptide Therapeutics Market size was evaluated to be around USD 47.67 billion in 2022 and is projected to expand at over 6.9% CAGR from 2023-2032 due to high prevalence of chronic and metabolic diseases along with high demand for novel therapeutics.
To get more details on this report: Request Free Sample PDF
Peptides are short chains of amino acids that are linked by peptide bonds. They are a unique class of compounds with therapeutic applications and play an important role within the cells, from signalling to anti-infectives. Peptide therapeutics act as essential replacement therapies that supplement peptide hormones when inadequate endogenous levels occur. Due to continuous research and development, the utilization of peptide therapeutics has evolved over time. Since the development of the first peptide therapeutic, insulin has showcased remarkable outcomes, which led to more research, development, and approval of around 80 peptide therapeutics all over the world.
Report Coverage | Details |
---|---|
Base Year: | 2022 |
Market Size in 2022: | USD 47.67 Billion |
Forecast Period: | 2023 to 2032 |
Forecast Period 2023 to 2032 CAGR: | 6.9% |
2032 Value Projection: | USD 92.89 Billion |
Historical Data for: | 2018 to 2022 |
No. of Pages: | 240 |
Tables, Charts & Figures: | 408 |
Segments covered: | Type, Application, Route of administration, Manufacturer type, Synthesis technology, Distribution channel, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
To get more details on this report: Request Free Sample PDF
COVID-19 has moderately impacted the growth of the peptide therapeutics market worldwide. Due to the therapeutic effect of peptide drugs, many of the peptide-based vaccines for the treatment of COVID-19 were in clinical trials. The continuous support and investments of the government in the research and development of peptide therapeutics will help expand this market. Around 21 peptide drugs, among which 15 are synthetic peptide drugs, were in development for treating acute respiratory distress syndrome (ARDS) and other respiratory issues caused by the SARS-CO-2 infection.
Cancer has become one of the leading causes of death worldwide. According to the GLOBOCAN report, in 2020, 19.3 million new cases of cancer were diagnosed, among which 10 million patients died due to cancer. The GLOBOCAN report predicts that in 2040, this number will grow and reach 28.4 million cancer cases all over the globe. Peptide therapeutics have emerged as a novel and promising treatment option for solid tumours like breast cancer. owing to the advantages of peptide therapeutics such as ease of synthesis, high target specificity and selectivity, and low toxicity, researchers have been focusing on developing novel and effective peptide therapeutics for many diseases, including cancer.
The prevalence of metabolic disorders is increasing all over the globe, leading to an growing demand for peptide therapeutics. Diabetes is one of the most common metabolic disorders that is treated using the peptide therapeutic insulin. Metabolic disorders and cancer are the main disease areas driving the utilisation of therapeutic drugs globally. According to International Diabetes Federation, in 2021, approximately 537 million adults are suffering from diabetes. The growing geriatric population, along with the increase in the incidence rate of infectious diseases, cardiovascular, respiratory, and other immune disorders, will propel the market trends.
The increased investments in developing novel therapeutics will boost this market. Increasing research and development in developing peptide therapeutics mainly focuses on oncology, metabolic disorders, and infectious diseases. The key players in this market are taking initiatives and investing more in the R&D of new drugs to retain their positions and develop novel drugs with higher efficacy to treat target diseases. Clinical trials related to such therapeutics have increased over the past decades.
To get more details on this report: Request Free Sample PDF
Based on type, the peptide therapeutics market is subdivided into branded and generic peptide. The branded peptide segment dominates the market in 2022 with revenue share of 61%. The prominent players in pharmaceutical industry are increasing the R&D investments and developing new drugs with higher prescription rates. In the coming years, generic peptides segment is expected to grow at higher pace due to the increasing healthcare expenditure and increased federal government healthcare spendings. The loss of patent is seen as an opportunity for generic segment to grow in this market.
Based on applications, the peptide therapeutics market is classified into metabolic disorders, cancer, cardiovascular, gastrointestinal, central nervous system, infectious diseases, respiratory disorders, pain management, renal disorders, dermatology, and other applications. The metabolic disorders segment accounted for the largest share in 2022 due to the high prevalence of metabolic diseases such as diabetes. During the forecast period, the cancer segment is expected to grow at a higher rate due to the increasing cases of cancer worldwide and the escalated utilisation of peptide therapeutics for treating cancer.
The increased demand for effective treatment options for treating diseases will boost this market. Increased awareness of the side effects of radiation and chemotherapy among patients has driven attention to peptide therapeutics, which have low toxicity. Hence, these factors will support the segment share.
Based on route of administration the peptide market is subdivided parenteral, oral, and other routes of administration. Parenteral segment held highest revenue share of market in 2022. This attributes to the factors like fast drug delivery, high adoption rate, and ease of administration.
To get more details on this report: Request Free Sample PDF
Based on manufacturer type, the peptide therapeutics market is classified into in-house and outsourced. The in-house segment dominated the market with the highest market share of around 68% in 2022 and is expected to grow at the highest CAGR during the forecast period. The key players are involved in developing the peptide therapeutics in-house because of the high cost associated with outsourcing and strict regulation.
Based on synthesis technology, the peptide therapeutics market is subdivided into liquid-phase peptide synthesis, solid-phase peptide synthesis, and hybrid technology. The liquid-phase peptide synthesis segment held the majority of market share in 2022. The high demand for pure peptides for developing effective therapeutics has facilitated the segment landscape. A significant growth in solid-phase peptide synthesis is expected as it lowers the synthesis time required for the production of peptides.
Based on distribution channel, the global peptide market is segmented into hospital, retail, and online pharmacies. The hospital pharmacies segment dominated the global market in 2022. As hospital pharmacies are primarily responsible for the availability of all the medications required in hospital.
Based on region, global peptide therapeutics market is subdivided into North America, Europe, Asia Pacific, Latin America, and the Middle East, and Africa. In 2022, the North America held the highest revenue in this market, owing to an increased prevalence of chronic diseases like cancer and diabetes, increasing investments for R&D for developing novel therapeutics, presence of key players, and increased healthcare expenditure are the factors contributing the growth of this segment.
The key players in peptide therapeutics market are Pfizer, Inc., Amgen, Inc., Bachem Holding AG, Eli Lilly and Company, Sanofi, AstraZeneca plc, AbbVie, GlaxoSmithKline plc, Baush Health, and Lonza Inc. These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches, etc. to maintain a competitive edge in the industry.
Click here to Buy Section of this Report
By Type
By Application
By Route of Administration
By Manufacturer Type
By Synthesis Technology
The above information is provided for the following regions and countries: